Showing results (211-220 of 262) with videos related to

Sort By:
Pageof 27
Blood|September 20, 2002
Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trialHervé Dombret, Jean Gabert, Jean-Michel Boiron, et al.
Blood|January 15, 2015
Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemiaNathalie Dhédin, Anne Huynh, Sébastien Maury, et al.
Leukemia Research|February 14, 2015
The p16(INK4A)/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcomeWei W Chien, Régine Catallo, Amel Chebel, et al.
American Journal of Hematology|July 28, 2015
Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experienceMarie-Anne Couturier, Françoise Huguet, Patrice Chevallier, et al.
Haematologica|December 8, 2018
Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotypeFrédéric Baron, Marian Stevens-Kroef, Michal Kicinski, et al.
World Journal of Stem Cells|January 12, 2018
High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemiaAdriana Plesa, Charles Dumontet, Eve Mattei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2017
Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First RemissionXavier Thomas, Stéphane de Botton, Sylvie Chevret, et al.
Blood Advances|January 17, 2024
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trialGail J Roboz, Guillermo Sanz, Elizabeth A Griffiths, et al.
Annals of Hematology|June 22, 2018
Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trialsFrédéric Baron, Marian Stevens-Kroef, Michal Kicinski, et al.
Lancet (London, England)|April 10, 2012
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 studySylvie Castaigne, Cécile Pautas, Christine Terré, et al.
Pageof 27